These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

642 related items for PubMed ID: 18334612

  • 1. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes.
    Cervera A, Wajcberg E, Sriwijitkamol A, Fernandez M, Zuo P, Triplitt C, Musi N, DeFronzo RA, Cersosimo E.
    Am J Physiol Endocrinol Metab; 2008 May; 294(5):E846-52. PubMed ID: 18334612
    [Abstract] [Full Text] [Related]

  • 2. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes.
    Linnebjerg H, Park S, Kothare PA, Trautmann ME, Mace K, Fineman M, Wilding I, Nauck M, Horowitz M.
    Regul Pept; 2008 Nov 29; 151(1-3):123-9. PubMed ID: 18675854
    [Abstract] [Full Text] [Related]

  • 3. Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus.
    Henkel E, Menschikowski M, Koehler C, Leonhardt W, Hanefeld M.
    Metabolism; 2005 Sep 29; 54(9):1168-73. PubMed ID: 16125528
    [Abstract] [Full Text] [Related]

  • 4. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
    Schwartz SL, Ratner RE, Kim DD, Qu Y, Fechner LL, Lenox SM, Holcombe JH.
    Clin Ther; 2008 May 29; 30(5):858-67. PubMed ID: 18555933
    [Abstract] [Full Text] [Related]

  • 5. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes.
    Linnebjerg H, Kothare PA, Skrivanek Z, de la Peña A, Atkins M, Ernest CS, Trautmann ME.
    Diabet Med; 2006 Mar 29; 23(3):240-5. PubMed ID: 16492205
    [Abstract] [Full Text] [Related]

  • 6. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
    Hücking K, Kostic Z, Pox C, Ritzel R, Holst JJ, Schmiegel W, Nauck MA.
    Diabet Med; 2005 Apr 29; 22(4):470-6. PubMed ID: 15787675
    [Abstract] [Full Text] [Related]

  • 7. Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects.
    Cersosimo E, Gastaldelli A, Cervera A, Wajcberg E, Sriwijilkamol A, Fernandez M, Zuo P, Petz R, Triplitt C, Musi N, DeFronzo RA.
    J Clin Endocrinol Metab; 2011 Jun 29; 96(6):1763-70. PubMed ID: 21411546
    [Abstract] [Full Text] [Related]

  • 8. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.
    DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L.
    Curr Med Res Opin; 2008 Oct 29; 24(10):2943-52. PubMed ID: 18786299
    [Abstract] [Full Text] [Related]

  • 9. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.
    Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD.
    J Clin Endocrinol Metab; 2003 Jul 29; 88(7):3082-9. PubMed ID: 12843147
    [Abstract] [Full Text] [Related]

  • 10. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
    Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, Taylor K.
    Diabetes Care; 2007 Jun 29; 30(6):1487-93. PubMed ID: 17353504
    [Abstract] [Full Text] [Related]

  • 11. Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program.
    Kirkman MS, Shankar RR, Shankar S, Shen C, Brizendine E, Baron A, McGill J.
    Diabetes Care; 2006 Sep 29; 29(9):2095-101. PubMed ID: 16936159
    [Abstract] [Full Text] [Related]

  • 12. Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes.
    Woerle HJ, Szoke E, Meyer C, Dostou JM, Wittlin SD, Gosmanov NR, Welle SL, Gerich JE.
    Am J Physiol Endocrinol Metab; 2006 Jan 29; 290(1):E67-E77. PubMed ID: 16105859
    [Abstract] [Full Text] [Related]

  • 13. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea.
    Mari A, Nielsen LL, Nanayakkara N, DeFronzo RA, Ferrannini E, Halseth A.
    Horm Metab Res; 2006 Dec 29; 38(12):838-44. PubMed ID: 17163361
    [Abstract] [Full Text] [Related]

  • 14. A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment.
    Gastaldelli A, Balas B, Ratner R, Rosenstock J, Charbonnel B, Bolli GB, Boldrin M, Balena R.
    Diabetes Obes Metab; 2014 Feb 29; 16(2):170-8. PubMed ID: 23911196
    [Abstract] [Full Text] [Related]

  • 15. Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection.
    Sheffield CA, Kane MP, Busch RS.
    Pharmacotherapy; 2007 Oct 29; 27(10):1449-55. PubMed ID: 17896900
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The effects of fiber enrichment of pasta and fat content on gastric emptying, GLP-1, glucose, and insulin responses to a meal.
    Frost GS, Brynes AE, Dhillo WS, Bloom SR, McBurney MI.
    Eur J Clin Nutr; 2003 Feb 29; 57(2):293-8. PubMed ID: 12571662
    [Abstract] [Full Text] [Related]

  • 18. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus.
    Schwartz EA, Koska J, Mullin MP, Syoufi I, Schwenke DC, Reaven PD.
    Atherosclerosis; 2010 Sep 29; 212(1):217-22. PubMed ID: 20557887
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1.
    Nauck MA, Walberg J, Vethacke A, El-Ouaghlidi A, Senkal M, Holst JJ, Gallwitz B, Schmidt WE, Schmiegel W.
    Regul Pept; 2004 Apr 15; 118(1-2):89-97. PubMed ID: 14759561
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.